{"schema_version":"secwatch.filing_event.v1","accession":"0001935979-23-000014","form_type":"8-K","ticker":"BHVN","cik":"0001935979","company_name":"Biohaven Ltd.","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.469508+00:00","generated_at":"2026-06-17T19:32:36.713489+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biohaven Q4 2022 net loss $201.1M; licenses TYK2/JAK1 inhibitor BHV-8000","bullets":["Q4 2022 net loss $201.1M ($3.32/share); cash $465.3M at year-end, no debt.","Acquired exclusive global ex-China rights to oral brain-penetrant TYK2/JAK1 inhibitor BHV-8000; Phase 1 start planned in 2023.","Completed Phase 1 SAD/MAD for Kv7 activator BHV-7000; no sedation/dizziness/ataxia; plans EEG study H1 2023 and pivotal H2 2023.","Appointed Bruce Car (CSO), Irfan Qureshi (CMO), Tanya Fischer (CDO) to management team."],"urls":{"canonical":"https://secwatch.observer/filing/0001935979-23-000014","json":"https://secwatch.observer/filing/0001935979-23-000014.json","markdown":"https://secwatch.observer/filing/0001935979-23-000014.md","text":"https://secwatch.observer/filing/0001935979-23-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1935979/000193597923000014/0001935979-23-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1935979/000193597923000014/bhvn-20230323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T19:32:36.713489+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"01d6d30b7a690fddb09dcd701abd0cfef87e8984","claim":"Biohaven Ltd. reported financial results for fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"On March 23, 2023, Biohaven Ltd. (the \" Registrant \") issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1935979/000193597923000014/0001935979-23-000014-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}